Drug persistence by group of treatment
| 1 year | 2 years | 3 years | |||||
| Retention rate (%) | 95% CI | Retention rate (%) | 95% CI | Retention rate (%) | 95% CI | P value | |
| All patients | 0.041 | ||||||
| TNFi | 69.2 | 68.2 to 70.3 | 55.3 | 54.1 to 56.5 | 45.2 | 43.9 to 46.5 | |
| JAKi | 68.3 | 66.0 to 70.6 | 54.0 | 51.4 to 56.5 | 44.9 | 42.1 to 47.7 | |
| Rheumatoid arthritis | 0.86 | ||||||
| TNFi | 67.4 | 65.7 to 69.0 | 52.9 | 51.0 to 54.7 | 42.6 | 40.5 to 44.6 | |
| JAKi | 68.3 | 66.0 to 70.6 | 54.0 | 51.4 to 56.5 | 44.9 | 42.1 to 47.7 | |
| Spondyloarthritis | |||||||
| Psoriatic arthritis | 0.016 | ||||||
| TNFi | 69.3 | 67.3 to 71.3 | 54.9 | 52.6 to 57.1 | 44.6 | 42.2 to 47.0 | |
| JAKi | 60.6 | 53.4 to 67.0 | 45.5 | 37.6 to 53.1 | 37.7 | 29.1 to 46.2 | |
| Axial spondyloarthritis | 0.30 | ||||||
| TNFi | 72.0 | 69.9 to 73.9 | 59.4 | 57.1 to 61.5 | 49.3 | 46.9 to 51.7 | |
| JAKi | 82.9 | 70.4 to 90.4 | 64.0 | 37.8 to 81.4 | 48.0 | 16.3 to 74.3 | |
Retention rate is expressed as estimated survival percentage, which accounted for the patients at risk in the denominator (ie, excluding censored subjects).
JAKi, Janus kinase inhibitor; TNFi, tumour necrosis factor inhibitor.